方唯意，男，1975年生，南方医科大学中西医结合医院中心实验室主任，研究员，博士生导师，博士后合作导师，中国研究型医院病毒与肿瘤委员会常委；中国抗癌协会肿瘤病因委员会青委和肿瘤标志委员会委员以及肿瘤标志委员会鼻咽癌专委会常委以及非编码RNA与肿瘤专委会常委。主要从事肿瘤药理与肿瘤病因发病学的研究。以通讯作者身份在Nature communications、Clinical Cancer Research、Signal transduction and targeted therapy（2）、Molecular Cancer（2）、Molecular therapy（2）、Oncogene（3）、Journal of Hematology & Oncology和Theranostics（2），International journal of biological sciences（3），Cancer letters（2），Journal  of experimental and clinical cancer research,molecular cancer等杂志上发表多篇论文，10分以上12篇。为国家科技部重点研发计划会评专家、国家青年拔尖人才计划以及科技部领军人才计划评审专家、国家自然科学基金肿瘤学处通讯评审专家以及广东省、四川省、江苏省、浙江省等多个自然科学基金评审专家；承担国家自然科学基金面上项目7项，广东省自然科学基金重点项目和面上项目多项以及广州市重点项目2项。此外，本人目前还作为Nature communications、Clinical cancer research、Oncogene、Theranostics、Molecular therapy、Signal transduction and targeted therapy、Journal of Hematology & Oncology、Molecular Therapy-Nucleic Acids等40多个SCI收录杂志特邀评审专家。

1.肿瘤发病机理研究

2.肿瘤耐药和逆转分子机理研究

       近5年代表性论文：

1.      Fu Q^#, Song X^#, Liu Z^#, Deng X^#, Luo R, Ge C, Li R, Li Z, Zhao M,Chen Y, Lin X, Zhang Q, Fang W^*. miRomics and Proteomics Reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc Feedback Loop Modulated by HDGF/DDX5/β-catenin Complex in Lung Adenocarcinoma. Clin Cancer Res. 2017;23(20):6336-6350.（IF:10.199）

2.      Li Y^#, Liu X^#, Lin X^#, Zhao M^#, Xiao Y, Liu C, Liang Z, Lin Z, Yi R, Tang Z, Liu J, Li X, Jiang Q, Li L, Xie Y, Liu Z^*, Fang W^*. Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9. Signal Transduct Target Ther. 2019;4:48. ( IF:18.187)

3.      Lin X^#, Li AM^#, Li YH^#, Luo RC^#, Zou YJ, Liu YY, Liu C, Xie YY, Zuo S, Liu Z, Liu Z^#*, Fang WY^*. Silencing MYH9 blocks HBx-induced GSK3beta ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):13. （IF: 13.493）

4.      Zhao M^#, Luo R^#, Liu Y^#, Gao L, Fu Z, Fu Q, Luo X, Chen Y, Deng X, Liang Z, Li X, Cheng C, Liu Z^*, Fang W^*. miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 2016;7:11309. （IF:12.124）

5.    Deng T, Shen P, Li A, Zhang Z, Yang H, Deng X, Peng X, Hu Z, Tang Z, Liu J, Hou R, Liu Z^*, Fang W^*.CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer. Theranostics. 2021 Jul 13;11(16):8112-8128.( IF:11.556)

6.Hou R, Li Y, Luo X, Zhang W, Yang H, Zhang Y, Liu J, Liu S, Han S, Liu C, Huang Y, Liu Z^*, Li A^*, Fang W^*. ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis. Int J Biol Sci. 2022 Mar 21;18(6):2553-2567. ( IF:10.750)

7.Hou R, Liu X^*, Yang H, Deng S, Cheng C, Liu J, Li Y, Zhang Y, Jiang J, Zhu Z, Su Y, Wu L, Xie Y, Li X, Li W, Liu ^*Z, Fang W^*. Chemically synthesized cinobufagin suppresses nasopharyngeal carcinoma metastasis by inducing ENKUR to stabilize p53 expression. Cancer Lett. 2022 Apr 10;531:57-70.( IF:9.756)

8.Zhang Z, Xu P, Hu Z, Fu Z, Deng T, Deng X, Peng L, Xie Y, Long L, Zheng D, Shen P, Zhang M, Gong B, Zhu Z, Lin J, Chen R, Liu Z, Yang H, Li R, Fang W. CCDC65, a Gene Knockout that leads to Early Death of Mice, acts as a potentially Novel Tumor Suppressor in Lung Adenocarcinoma. Int J Biol Sci. 2022 Jun 27;18(10):4171-4186.( IF:10.750)

9.Liu JH, Yang HL, Deng ST, Hu Z, Chen WF, Yan WW, Hou RT, Li YH, Xian RT, Xie YY, Su Y, Wu LY, Xu P, Zhu ZB, Liu X, Deng YL, Wang YB^*, Liu Z^*, Fang WY^*. The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma. Acta Pharmacol Sin. 2022 Mar 16. doi: 10.1038/s41401-022-00890-x. Epub ahead of print. ( IF：8.1)

10.10.Tao X#, Li Y#, Fan S#, Wu L#, Xin J, Su Y, Xian X, Huang Y, Huang R, Fang W*, Liu Z*. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma. J Exp Clin Cancer Res. 2023 Jan 10;42(1):12. （IF:11.4）

11.Zhang Z, Huang H, Peng L, Zhou B, Yang H, Tang Z, Yan W, Chen W, Liu Z, Zheng D, Shen P, Fang W. SIX4 Activation in Inflammatory Response Drives the Transformation of Colorectal Epithelium into Inflammation and Tumor via Feedback-Enhancing Inflammatory Signaling to Induce Tumor Stemness Signaling. Int J Biol Sci. 2024 Aug 26;20(12):4618-4634. ( IF：8.2)